

#### Nippon Shinyaku 6th Five-Year Medium-term Management Plan (FY2019-FY2023)

## Aiming for Sustainable Growth –Pursuit of Further Originality–

May 15, 2019 Nippon Shinyaku Co., Ltd. President and Representative Director Shigenobu Maekawa






#### **5th Five-Year Medium-term Management Plan**

#### Aiming for New Growth -Pursuit of Originality-







Net sales and Operating profit have steadily grown during the term of the 5th Plan.











**R&D** Strategy

Enhance our pipeline to launch products continuously in the areas of focus

Launched seven products including Zalutia and Uptravi

Enhanced our pipeline by concluding license agreements for six products including NS-73 and NS-32

Reduce cost and speed up R&D by building a manufacturing facility for APIs for clinical trials

Completed the manufacturing facility for APIs for clinical trials in March 2016, promptly manufactured nucleic acid API, and sped up R&D

Marketing Strategy

Develop product groups in three areas (PAH, urology, hematology) into drivers of growth

Vidaza and Zalutia became drivers of growth with sales of more than 10 billion yen
Awareness in PAH area increased by the launch of Uptravi and Opsumit and our information provision activities

Supply Chain Strategy

Invest in a manufacturing facility for highly active medicines and manufacture our original products

Completed the manufacturing facility for highly active medicines in July 2017 and proceeding with in-house manufacturing of Uptravi

#### Qualitative Target Assessment for the Term of the 5th Plan (2)



**Overseas Business Strategy** 

Choose the best way to expand our business according to each country's situation

Uptravi: launched in many countries and greatly contributed to the growth
NS-065/NCNP-01: proceeded with preparations for US NDA and establishment of sales organization

**Functional Food Business** 

Transform functional food business into a highly profitable entity

Significantly improved the operating profit on sales of functional food business
Started supplement business and built a foundation for transformation

Human Resource Strategy


Improve recruitment and employee training ("Human resources are the base of originality")

- Introduced a flextime system for medical representatives first in the Japanese pharmaceutical industry
- Hired outside personnel with a high level of expertise

 Recognized under the Certified Health and Productivity Management Organization Recognition Program (White 500)

#### Summary and Outlook for the Next Plan









#### 6th Five-Year Medium-term Management Plan

#### Aiming for Sustainable Growth –Pursuit of Further Originality–





Measures to promote greater use of generics Drug price reduction to curb medical expenses

Declining birthrate Aging population Decrease in working population Arrival of the era of centenarians Diversification in work style


Diversification in modality of drug discovery Progress of precision medicine Penetration of health/preventionoriented mindset

Actions outside the existing framework are needed for sustainable growth



#### Six Actions in the 6th Plan





## Corporate vision: company with a meaningful existence in healthcare

🕟 NIPPON SHINYAKU CO., LTD.



### Action 1


#### Creation of new value through R&D



#### **Pharmaceutical R&D Strategy**



Expand the range of drug discovery to create new value by adding new modalities and technologies to our drug discovery platform where we created a small molecule drug NS-304 and a nucleic acid drug NS-065/NCNP-01.



#### Products to be Launched during the Term of the 6th Plan



#### Products of which we aim for approval by FY2023

Original		NS-065/NCNP-01 DMD in Japan and overseas	Exon 44 s DMD	ping drug apan and overseas	NS-018 Myelofibrosi	S Overseas
License-in		NS-73 in Japan Veno-occlusive disease (treatment)		NS-73 Veno-occlusive	e disease (prev	in Japan ention)
se-in		NS-32 Iron deficiency anemia	in Japan	ZX008 Intractable epil	epsy	in Japan
PLCM		NS-304 Chronic thromboembolic pulmonal	in Japan ry hypertension	NS-304 Arteriosclerosi	s obliterans	in Japan
CM		Macitentan Chronic thromboembolic pulmonal	in Japan ry hypertension	NS-17 AML		in Japan


#### Products of which we aim for approval in the near future after FY2024

NS-580	NS-304	NS-87	NS-917					
Endometriosis	Lumbar spinal stenosis	Secondary AML	Relapsed/refractory AML					
DMD treatments other than NS-065/NCNP-01 and Exon 44 skipping drug								

DMD: Duchenne muscular dystrophy AML: Acute myeloid leukemia



Continuously launch highly original new products by enhancing R&D capability







# Action **2**

### **Development of global business**





Global original product Uptravi

Maximize product value by further strengthening cooperation with partners Deliver unique products to the US and all over the world

Build an organizational structure suitable to the development of global business in Global Business Division, US subsidiary, and all departments of R&D, manufacture, distribution and sales

#### Further accelerate the expansion of our global business



#### US business

- Prepare for NS-065/NCNP-01 launch, establish sales organization
- Invest in R&D of nucleic acid drugs after NS-065/NCNP-01
- Enhance product pipeline

#### Europe/China business

- Aim for early approval of NS-065/NCNP-01
- Consider sales organization





### Action **③**

### Increase in corporate value by strengthening ESG management



#### **Actions for ESG Management**







We recognize that to pass on nature's bounty to future generations is a mission imposed on a company which continuously practices business activities. We will work to reduce our impact on the environment.





We will increase the satisfaction and diversity of our employees creating new products, based on the idea that patients' and customers' satisfaction leads to contributions to society and ultimately to the company's sustainable growth.



We recognize that it is a critical management priority to be transparent and accountable to all stakeholders. We will work non-stop to enhance corporate governance.



### Action **4**

## Creation of organizational climate in which each employee can be active



#### **Promotion of Motivation Management**



"Unique products come from unique human resources" Respect diversity and provide opportunities for each employee to proactively take on challenges and grow

#### Changes in working environment

Decrease in working generation due to declining birthrate and aging population Increase in senior generation

Changes in work style of child-raising generation

Increase in caregiving generation

Globalization of business

Growth of working generation Active senior generation Active child-raising and caregiving generations Increase in productivity

Revision of personnel systems and their operation

Measures to streamline operations by using AI and RPA


Cultivation of next-generation leaders and global human resources

Promotion of Health and Productivity Management

Allow employees to work in diverse ways and to try various things. Create an organizational climate in which each employee can proactively take on challenges and grow.



- Actively recruit new graduates and mid-career workers to deal with business expansion
- Increase productivity per employee using AI, IoT and RPA
  - ⇒ The number of employees at the end of FY2023 will be slightly more than 2,000 at the end of FY2018








### Action **5**

#### Active use of AI and adoption of IT



#### Active Use of AI and Investment in IT Adoption



We will accelerate launch of new products, streamline operations and increase productivity by actively using AI, RPA and other technologies, and by promoting adoption of IT.





## Action **(3)**

## Further strengthening of management base



#### **Further Strengthening of Management Base**





Achieve Sustainable Growth



## 6th Medium-term Management Plan Numerical Target for FY2023






	Targets	CAGR		
Net sales	¥150,000 mil	5.5%		
Pharmaceuticals	¥133,000 mil	5.8%		
Functional Food	¥17,000 mil	3.4%		
Operating profit	¥40,000 mil	14.2%		
Profit attributable to owners of parent	¥30,000 mil	13.0%		
EPS	¥445	13.0%		
ROE	10% or more throughout the term			



#### **Strengthening of Strategic Investment**










## **Basic Policy for Return to Shareholders**





Increase the consolidated payout ratio to around 35% and aim to raise annual cash dividends per share by increasing EPS.








#### Nippon Shinyaku Basic Policy

Nippon Shinyaku Co., Ltd.



33



#### **Safe Harbor Statement**

- Materials and information provided during this presentation may contain so-called "forwardlooking statements." These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements.
- Risks and uncertainties include general industry and market conditions, and general domestic and international economic conditions such as interest rate and currency exchange fluctuations. Risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, technological advances and patents attained by competitors; challenges inherent in new product development, including completion or failure of clinical trials; claims and concerns about product safety and efficacy; regulatory agency's examination, obtaining regulatory approvals; domestic and foreign social security reforms; trends toward healthcare cost containment; and governmental laws and regulations affecting domestic and foreign operations.
- Also, for products that are approved, there are manufacturing and marketing risks and uncertainties, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials, and competition with others.
- The Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
- This English presentation was translated from the original Japanese version. In the event of any inconsistency between the statements in the two versions, the statements in the Japanese version shall prevail.

#### S NIPPON SHINYAKU CO., LTD.